The Cardiovascular Prevention Program

Summary

Cardiovascular diseases represent one of the main public health problems being the leading cause of morbidity, disability and mortality. In recent decades, the global prevalence and cardiovascular disease mortality has increased, with 23.6 million annual deaths expected by 2030. In Europe, mortality per year is equal to 2.2 million women and 1.9 million men, representing 47% and 37% of all deaths respectively. In Italy, the situation in terms of deaths due to cardiovascular diseases it is in line with the world ranking and European, being responsible for 44% of all deaths. The only interventional or pharmacological approach is neither effective nor sustainable. The most deaths from cardiovascular diseases are due to atherothrombotic events, which are attributable to a series of risk factors, most of which are modifiable. Turns out itself as a targeted action on these factors with the aim of safeguarding the state of health cardiovascular, may represent the best applicable strategy. It is therefore necessary structure and activate prevention programs aimed at the general population and groups of subjects at higher risk.

Conditions

• Cardiovascular Prevention

Interventions

OTHER

International Physical Activity Questionnaire

Assessments of physical activity level and functional capabilities (aerobic capacity, muscular strength and power, flexibility

OTHER

Six minute walking test

The 6 Minute Walk Test is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.

OTHER

SF-36, Euro-Qol 5D-5L, Perceived stress scale-10, Pittsburgh Sleep Quality Index, Depression Anxiety Stress scale- 21.

Evaluation of the quality of life, the psychological sphere (anxiety, stress, depression) and the quality of sleep

OTHER

MEDAS

Evaluation of adherence to the Mediterranean diet

OTHER

Intima-media thickness (IMT)

Bmode ultrasonography

BIOLOGICAL

Blood sampling

Measurement of parameters for defining cardiovascular risk and biomarkers.

BIOLOGICAL

Stool Sample Culture Test

Evaluation of Gut Microbiota

Sponsors & Collaborators

• Maria Cecilia Hospital

  lead OTHER

Principal Investigators

• Anna Maria Malagoni · Maria Cecilia Hospital

Study Design

Allocation

NA

Purpose

PREVENTION

Masking

NONE

Model

SEQUENTIAL

Eligibility

Min Age

18 Years

Max Age

30 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2024-05-13

Primary Completion

2027-04-15

Completion

2027-04-15

Countries

• Italy

Study Locations